Two-year ORIGIN 3 data show weekly atacicept flattened eGFR decline to 0.6 mL/min per year and cut kidney-progression events by 76 percent, with no dialysis or transplants on drug.
Newsletter
Pipeline, markets, policy, and science. Once a week.
KRAS sat on the undruggable list for decades. Silexion's SIL204 is built to silence the mutation earlier in the cell, and the Phase 2/3 program is now moving into patients.
Del-desiran missed its primary endpoint in myotonic dystrophy type 1, wiping 13% off Novartis, pulling rival Dyne down 22%, and casting doubt over TfR1 RNA delivery.
The FDA granted accelerated approval to AstraZeneca’s camizestrant based on ctDNA resistance signals before radiographic progression, overruling a 6-3 advisory committee vote and betting on a new oncology paradigm.